Rossari Biotech Reports Q3 Profit, Revenue Surge; Margins Contract to 11.8%

• Rossari Biotech, a Mumbai-based specialty chemical maker, announced its Q3 earnings on January 17.
• Net profit increased by 3.2% to ₹32.7 crore, up from ₹31.7 crore in the previous year.
• Revenue saw a 13.4% rise, reaching ₹581.6 crore compared to ₹512.7 crore in the prior fiscal's Q3.
• EBITDA grew 6.3% annually to ₹68.8 crore from ₹64.7 crore.
• Despite growth in profit and revenue, the company's margin contracted to 11.8% from 12.6%.

Why It Matters: Rossari Biotech's Q3 saw increased profit and revenue, but margins tightened due to rising costs.